0001129928-26-000033
SEC filingOncolytics Biotech reported a $9.2M net loss and $7.3M net cash outflow from operations in Q1 FY2026, reflecting continued investment in clinical and manufacturing readiness while relying on its equity distribution agreement to meet near-term liquidity needs.
Oncolytics Biotech reported an operating loss of $9.3M for Q1 FY2026. As a clinical-stage biopharmaceutical company with no approved products or commercial revenue, this result reflects the expected cost structure of advancing late-stage development programs and supporting manufacturing readiness. The loss includes personnel-related expenses, notably increased stock-based compensation arising from new stock option grants in the second half of 2025 and the reclassification of certain options from equity to liability classification, as described in Note 3.
Net income totaled $9.2M in loss for the quarter, nearly aligned with operating income, confirming minimal non-operating activity. Diluted EPS was $-0.08, derived from allocating the net loss across the weighted-average number of diluted common shares outstanding during the period. This metric underscores the impact of current losses on shareholder value metrics without implying operational scale or profitability inflection.
Net cash used in operating activities was $7.3M, reflecting the net loss adjusted for non-cash items and changes in working capital. Management attributes non-cash working capital changes primarily to decreased other liabilities — resulting from the utilization of prior funding, including support from PanCAN — and increases in accounts payable and accrued liabilities. These dynamics are consistent with the timing of vendor payments and the drawdown of previously received non-dilutive funding.
Capital expenditures were nominal at $6,000, limited to essential lab or equipment upgrades supporting ongoing R&D infrastructure. Free cash flow — defined as net cash provided by (used in) operating activities less capital expenditures — was therefore $7.3M in outflow. This confirms that operational cash needs remain fully funded externally, with no material investment in long-lived assets during the quarter.